Logo
x

Search category

Subscribe Now

Eli Lilly

Eli Lilly Publishes P-IIa Study Results of Peresolimab for the Treatment of Rheumatoid Arthritis in the NEJM

Eli Lilly Publishes P-IIa Study Results of Peresolimab for the Treatment of Rheumatoid Arthritis in the NEJM

  • May 19, 2023
Insights+ Key Biosimilars Events of April 2023

Insights+ Key Biosimilars Events of April 2023

  • May 4, 2023
Eli Lilly Reports P-III Study (TRAILBLAZER-ALZ 2) Results of Donanemab for the Treatment of Early Alzheimer's Disease

Eli Lilly Reports P-III Study (TRAILBLAZER-ALZ 2) Results of Donanemab for the Treatment of Early Alzheimer's Disease

  • May 3, 2023
Eli Lilly Presents P-III Clinical Development Program Results of Lebrikizumab for Atopic Dermatitis at 5th Annual RAD Congress

Eli Lilly Presents P-III Clinical Development Program Results of Lebrikizumab for Atopic Dermatitis at 5th Annual RAD Congress

  • May 3, 2023
Eli Lilly Reports P-III Trial (SURMOUNT-2) Results of Tirzepatide for Obesity or Overweight and Type 2 Diabetes

Eli Lilly Reports P-III Trial (SURMOUNT-2) Results of Tirzepatide for Obesity or Overweight and Type 2 Diabetes

  • April 27, 2023
Eli Lilly to Sell Baqsimi to Amphastar for ~$1B

Eli Lilly to Sell Baqsimi to Amphastar for ~$1B

  • April 25, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.